175 related articles for article (PubMed ID: 34910361)
1. A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007.
Zalles M; Smith N; Saunders D; Lerner M; Fung KM; Battiste J; Towner RA
J Cell Mol Med; 2022 Jan; 26(2):570-582. PubMed ID: 34910361
[TBL] [Abstract][Full Text] [Related]
2. Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model.
Zalles M; Smith N; Ziegler J; Saunders D; Remerowski S; Thomas L; Gulej R; Mamedova N; Lerner M; Fung KM; Chung J; Hwang K; Jin J; Wiley G; Brown C; Battiste J; Wren JD; Towner RA
J Cell Mol Med; 2020 Jan; 24(2):1738-1749. PubMed ID: 31863639
[TBL] [Abstract][Full Text] [Related]
3. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.
Ziegler J; Pody R; Coutinho de Souza P; Evans B; Saunders D; Smith N; Mallory S; Njoku C; Dong Y; Chen H; Dong J; Lerner M; Mian O; Tummala S; Battiste J; Fung KM; Wren JD; Towner RA
Neuro Oncol; 2017 Feb; 19(2):175-185. PubMed ID: 27416955
[TBL] [Abstract][Full Text] [Related]
4. ELTD1 as a multi-focal target for malignant gliomas: preclinical studies.
Zalles M; Smith N; Saunders D; Guzman M; Lerner M; Fung KM; Babu A; Battiste J; Chung J; Hwang K; Jin J; Towner RA
Neurooncol Adv; 2021; 3(1):vdab132. PubMed ID: 34704036
[TBL] [Abstract][Full Text] [Related]
5. Targeting ELTD1, an angiogenesis marker for glioblastoma (GBM), also affects VEGFR2: molecular-targeted MRI assessment.
Ziegler J; Zalles M; Smith N; Saunders D; Lerner M; Fung KM; Patel M; Wren JD; Lupu F; Battiste J; Towner RA
Am J Nucl Med Mol Imaging; 2019; 9(1):93-109. PubMed ID: 30911439
[TBL] [Abstract][Full Text] [Related]
6. Assessment of an scFv Antibody Fragment Against ELTD1 in a G55 Glioblastoma Xenograft Model.
Zalles M; Smith N; Saunders D; Saran T; Thomas L; Gulej R; Lerner M; Fung KM; Chung J; Hwang K; Jin J; Battiste J; Towner RA
Transl Oncol; 2020 Mar; 13(3):100737. PubMed ID: 32208341
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Pediatric Glioblastoma Tumor Growth by the Anti-Cancer Agent OKN-007 in Orthotopic Mouse Xenografts.
Coutinho de Souza P; Mallory S; Smith N; Saunders D; Li XN; McNall-Knapp RY; Fung KM; Towner RA
PLoS One; 2015; 10(8):e0134276. PubMed ID: 26248280
[TBL] [Abstract][Full Text] [Related]
8. OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth.
Towner RA; Smith N; Saunders D; Brown CA; Cai X; Ziegler J; Mallory S; Dozmorov MG; Coutinho De Souza P; Wiley G; Kim K; Kang S; Kong DS; Kim YT; Fung KM; Wren JD; Battiste J
Transl Oncol; 2019 Feb; 12(2):320-335. PubMed ID: 30468988
[TBL] [Abstract][Full Text] [Related]
9. Targeting nitric oxide and NMDA receptor-associated pathways in treatment of high grade glial tumors. Hypotheses for nitro-memantine and nitrones.
Altinoz MA; Elmaci İ
Nitric Oxide; 2018 Sep; 79():68-83. PubMed ID: 29030124
[TBL] [Abstract][Full Text] [Related]
10. Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007.
Towner RA; Gillespie DL; Schwager A; Saunders DG; Smith N; Njoku CE; Krysiak RS; Larabee C; Iqbal H; Floyd RA; Bourne DW; Abdullah O; Hsu EW; Jensen RL
Neuro Oncol; 2013 Mar; 15(3):330-40. PubMed ID: 23328810
[TBL] [Abstract][Full Text] [Related]
11. Novel approaches to combat chemoresistance against glioblastomas.
Towner RA; Zalles M; Saunders D; Smith N
Cancer Drug Resist; 2020; 3(4):686-698. PubMed ID: 35582224
[TBL] [Abstract][Full Text] [Related]
12. ELTD1 as a biomarker for multiple sclerosis: Pre-clinical molecular-targeted studies in a mouse experimental autoimmune encephalomyelitis model.
Towner RA; Smith N; Zalles M; Morris S; Toliver M; Saunders D; Lerner M; Kumar G; Axtell RC
Mult Scler Relat Disord; 2021 Apr; 49():102786. PubMed ID: 33517175
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory agent, OKN-007, reverses long-term neuroinflammatory responses in a rat encephalopathy model as assessed by multi-parametric MRI: implications for aging-associated neuroinflammation.
Towner RA; Saunders D; Smith N; Gulej R; McKenzie T; Lawrence B; Morton KA
Geroscience; 2019 Aug; 41(4):483-494. PubMed ID: 31478121
[TBL] [Abstract][Full Text] [Related]
14. OKN-007 decreases tumor necrosis and tumor cell proliferation and increases apoptosis in a preclinical F98 rat glioma model.
de Souza PC; Balasubramanian K; Njoku C; Smith N; Gillespie DL; Schwager A; Abdullah O; Ritchey JW; Fung KM; Saunders D; Jensen RL; Towner RA
J Magn Reson Imaging; 2015 Dec; 42(6):1582-91. PubMed ID: 25920494
[TBL] [Abstract][Full Text] [Related]
15. ELTD1, a potential new biomarker for gliomas.
Towner RA; Jensen RL; Colman H; Vaillant B; Smith N; Casteel R; Saunders D; Gillespie DL; Silasi-Mansat R; Lupu F; Giles CB; Wren JD
Neurosurgery; 2013 Jan; 72(1):77-90; discussion 91. PubMed ID: 23096411
[TBL] [Abstract][Full Text] [Related]
16. Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth.
Lee J; Shin YJ; Lee K; Cho HJ; Sa JK; Lee SY; Kim SH; Lee J; Yoon Y; Nam DH
Cancer Res Treat; 2018 Jul; 50(3):1009-1022. PubMed ID: 29129044
[TBL] [Abstract][Full Text] [Related]
17. ELTD1 Review: New Regulator of Angiogenesis in Glioma.
Buzatu I; Tache DE; Manea Carneluti EV; Zlatian O
Curr Health Sci J; 2023; 49(4):495-502. PubMed ID: 38559823
[TBL] [Abstract][Full Text] [Related]
18. Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models.
Jarzabek MA; Amberger-Murphy V; Callanan JJ; Gao C; Zagozdzon AM; Shiels L; Wang J; Ligon KL; Rich BE; Dicker P; Gallagher WM; Prehn JH; Byrne AT
Br J Cancer; 2014 Dec; 111(12):2275-86. PubMed ID: 25375271
[TBL] [Abstract][Full Text] [Related]
19. ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma.
Huang H; Georganaki M; Conze LL; Laviña B; van Hooren L; Vemuri K; van de Walle T; Ramachandran M; Zhang L; Pontén F; Bergqvist M; Smits A; Betsholtz C; Dejana E; Magnusson PU; He L; Lugano R; Dimberg A
Neuro Oncol; 2022 Mar; 24(3):398-411. PubMed ID: 34347079
[TBL] [Abstract][Full Text] [Related]
20. OKN-007 Alters Protein Expression Profiles in High-Grade Gliomas: Mass Spectral Analysis of Blood Sera.
Towner RA; Hocker J; Smith N; Saunders D; Battiste J; Hanas J
Brain Sci; 2022 Jan; 12(1):. PubMed ID: 35053843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
